Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease

被引：0
|
作者：
Milosevic, V. [1 ]
Petrovic, M. [1 ]
Mihaljevic, B. [1 ]
Jankovic, S. [1 ]
Nedeljkov, R. Jancic [1 ]
Boskovic, D. [1 ]
机构：
[1] Inst Hematol, Belgrade, Serbia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1239
引用
收藏
页码：451 / 451
页数：1
相关论文
共 50 条
  • [21] GEMCITABINE, DEXAMETHASONE AND CISPLATIN IS EFFECTIVE AS A SALVAGE CHEMOTHERAPY REGIMEN IN RELAPSED OR REFRACTORY HODGKIN'S DISEASE PRIOR TO ASCT
    Precupanu, C. M.
    Senecal, D.
    Lissandre, S.
    Delain, M.
    Dartigeas, C.
    Radesi, S.
    Venel, Y.
    Benboubker, L.
    Herault, O.
    Colombat, P.
    Gyan, E.
    HAEMATOLOGICA, 2012, 97 : 564 - 564
  • [22] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma
    Dumontet, C
    Morschhauser, F
    Solal-Celigny, P
    Bouafia, F
    Bourgeois, E
    Thieblemont, C
    Leleu, X
    Hequet, O
    Salles, G
    Coiffier, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 772 - 778
  • [23] Prolonged infusion of gemcitabine in refractory Hodgkin's disease.
    Sezer, O
    Eucker, J
    Jakob, C
    Schmid, P
    Possinger, K
    BLOOD, 2000, 96 (11) : 248B - 248B
  • [24] Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin's disease
    Lueke, F.
    Harrer, D. C.
    Menhart, K.
    Wolff, D.
    Holler, E.
    Hellwig, D.
    Herr, W.
    Grube, M.
    Vogelhuber, M.
    Reichle, A.
    Heudobler, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 90
  • [25] Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's Disease
    Lueke, Florian
    Harrer, Dennis C.
    Menhart, Karin
    Wolff, Daniel
    Holler, Ernst
    Hellwig, Dirk
    Herr, Wolfgang
    Grube, Matthias
    Vogelhuber, Martin
    Reichle, Albrecht
    Heudobler, Daniel
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] Ifosfamide, gemcitabine, and vinorelbine: a now induction regimen for refractory and relapsed Hodgkin's lymphoma
    Santoro, Armando
    Magagnoli, Massimo
    Spina, Michele
    Pinotti, Graziella
    Siracusano, Licia
    Michieli, Mariagrazia
    Nozza, Andrea
    Sarina, Barbara
    Morenghi, Emanuela
    Castagna, Luca
    Tirelli, Umberto
    Balzarotti, Monica
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 35 - 41
  • [27] Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 6 - 9
  • [28] An update on the management of relapsed and primary refractory Hodgkin's disease
    Moskowitz, C
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 54 - 59
  • [29] Treatment of relapsed and refractory Hodgkin Lymphoma
    von Tresckow, Bastian
    Moskowitz, Craig H.
    SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 180 - 185
  • [30] Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives
    Brusamolino, Ercole
    Carella, Angelo Michele
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 6 - 10
12345